aTyr Pharma’s Trial Failure Sparks Shareholder Lawsuit

aTyr Pharma promised investors a breakthrough. Executives said their drug, efzofitimod, could let lung disease patients taper off steroids entirely — calling it a “paradigm-shifting therapy.”

From January through August 2025, aTyr kept repeating that confidence. The Phase Three trial, they said, was “well-powered,” fully enrolled, and on track for “major catalyst” results.

Then came September 15th. The company revealed the study had failed its primary goal — efzofitimod didn’t significantly reduce steroid use compared to placebo. Analysts slashed price targets from sixteen dollars to as low as one.

The stock collapsed about eighty three percent in one day, falling from just over $6 to nearly $1. Investors were blindsided, trust gone.

Now, more investors are joining the lawsuit.